Advances in biologic and small molecule therapies for hidradenitis suppurativa
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in biologic and small molecule therapies for hidradenitis suppurativa
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-20
Publisher
Informa UK Limited
Online
2022-04-26
DOI
10.1080/14656566.2022.2070429
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting
- (2021) S. Ribero et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs
- (2021) Zachary E. Holcomb et al. Expert Opinion On Drug Safety
- Bimekizumab versus Adalimumab in Plaque Psoriasis
- (2021) Richard B. Warren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti‐TNF and anti‐ interleukin‐17 failures
- (2021) Raffaele Dante Caposiena Caro et al. Dermatologic Therapy
- Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
- (2021) Juliana Setyawan et al. DRUG SAFETY
- Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure
- (2021) Maria del Mar Melendez-Gonzalez et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
- (2021) James G. Krueger et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
- (2021) Sophie Glatt et al. JAMA Dermatology
- Prevalence of Hidradenitis Suppurativa
- (2021) Abdulhadi Jfri et al. JAMA Dermatology
- Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
- (2021) Falk G. Bechara et al. JAMA Surgery
- Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for adalimumab
- (2020) E.J. Giamarellos‐Bourboulis et al. BRITISH JOURNAL OF DERMATOLOGY
- A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain
- (2020) Alice Gottlieb et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Results of an Open-Label Trial
- (2020) Rachel G. Casseres et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- IL‐17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa
- (2020) Jean M. Fletcher et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
- (2020) April W. Armstrong et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Effect of Subcutaneous Brodalumab upon Clinical Disease Activity in Hidradenitis Suppurativa: An Open Label Cohort Study
- (2020) John W. Frew et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effectiveness of secukinumab in Hidradenitis Suppurativa : an open study (20 cases)
- (2020) Z. Reguiaï et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Weekly Administration of Brodalumab in Hidradenitis Suppurativa: An Open Label Cohort Study
- (2020) J.W. Frew et al. BRITISH JOURNAL OF DERMATOLOGY
- Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction
- (2020) Eva M. Sánchez‐Martínez et al. Dermatologic Therapy
- Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System
- (2020) Georgios Kokolakis et al. DERMATOLOGY
- Long‐term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open‐label phase 3 results
- (2020) Akimichi Morita et al. JOURNAL OF DERMATOLOGY
- Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after anti‐TNF failure
- (2020) E. Marques et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy
- (2020) Iris Wohlmuth‐Wieser et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis
- (2020) M. Kaul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)
- (2019) Xingrui He et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- The Immune System Computes the State of the Body: Crowd Wisdom, Machine Learning, and Immune Cell Reference Repertoires Help Manage Inflammation
- (2019) Irun R. Cohen et al. Frontiers in Immunology
- Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa
- (2019) L. Prussick et al. BRITISH JOURNAL OF DERMATOLOGY
- Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
- (2019) G. Yosipovitch et al. BRITISH JOURNAL OF DERMATOLOGY
- Determining the Optimal Dose of Infliximab for Treatment of Hidradenitis Suppurativa
- (2019) Ashley N. Oskardmay et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis
- (2019) J.J. Crowley et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa
- (2019) Jorge Romaní et al. DERMATOLOGY
- Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa
- (2019) Akimichi Morita et al. JOURNAL OF DERMATOLOGY
- Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa
- (2019) David Grand et al. EXPERIMENTAL DERMATOLOGY
- High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa
- (2019) Mondana H. Ghias et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Association between hidradenitis suppurativa, depression, anxiety, and suicidality: A systematic review and meta-analysis
- (2019) Kevin R. Patel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study
- (2018) Theodora Kanni et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial
- (2018) Allard R.J.V. Vossen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study
- (2018) Christos C. Zouboulis et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy
- (2018) Zihao Xu et al. Frontiers in Immunology
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa
- (2018) Martina L Porter et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy
- (2017) Victoria K. Shanmugam et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Canakinumab for Severe Hidradenitis Suppurativa
- (2017) Carine Houriet et al. JAMA Dermatology
- Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
- (2016) J.L. Blok et al. BRITISH JOURNAL OF DERMATOLOGY
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
- (2016) Alexa B. Kimball et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
- (2016) Torbjörn Kullenberg et al. RHEUMATOLOGY
- Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa
- (2016) Vassiliki Tzanetakou et al. JAMA Dermatology
- Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies
- (2015) Diane R. Mould et al. JOURNAL OF CLINICAL PHARMACOLOGY
- HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study
- (2015) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease
- (2014) Iris Dotan et al. INFLAMMATORY BOWEL DISEASES
- Tumour Necrosis Factor-alpha and Matrix Metalloproteinase-2 are Expressed Strongly in Hidradenitis Suppurativa
- (2013) E Mozeika et al. ACTA DERMATO-VENEREOLOGICA
- Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
- (2013) Alexa B. Kimball et al. ANNALS OF INTERNAL MEDICINE
- Four-weekly infliximab in the treatment of severe hidradenitis suppurativa
- (2013) B. Moriarty et al. BRITISH JOURNAL OF DERMATOLOGY
- An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa
- (2013) Kieron S. Leslie et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review
- (2013) Renée M Marchioni WORLD JOURNAL OF GASTROENTEROLOGY
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
- (2012) Uma Mahadevan et al. Clinical Gastroenterology and Hepatology
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Long-term efficacy of infliximab in hidradenitis suppurativa
- (2012) Sabela Paradela et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
- (2011) I. Miller et al. BRITISH JOURNAL OF DERMATOLOGY
- Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β
- (2011) H.H. van der Zee et al. BRITISH JOURNAL OF DERMATOLOGY
- Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study
- (2011) H.H. van der Zee et al. BRITISH JOURNAL OF DERMATOLOGY
- Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
- (2011) A.A. Fasanmade et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
- (2011) Christoph Schlapbach et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF
- (2011) Gillian A. Hawker et al. ARTHRITIS CARE & RESEARCH
- Treatment of Hidradenitis Suppurativa With Etanercept Injection
- (2010) David R. Adams et al. ARCHIVES OF DERMATOLOGY
- Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy
- (2010) Monika Arenbergerova et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial
- (2010) Annika Grant et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Transmembrane TNF- : structure, function and interaction with anti-TNF agents
- (2010) T. Horiuchi et al. RHEUMATOLOGY
- Increased Serum Tumour Necrosis Factor- in Hidradenitis Suppurativa Patients: Is There a Basis for Treatment with Anti-Tumour Necrosis Factor- Agents?
- (2009) L Matusiak et al. ACTA DERMATO-VENEREOLOGICA
- A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa
- (2009) Robert A. Lee et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More